BioRestorative Therapies, Inc. (BRTX)
NASDAQ
Healthcare
Biotechnology
$0.39
▼ -1.73%
Market Cap
$3.5M
Sector
Healthcare
Industry
Biotechnology
Beta
0.58
52-Wk Range
0.1593-1.89
CEO
Lance Alstodt
Country
US
Currency
USD
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1…
Open full interactive analysis & DCF →